[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación Santiago Dexeus Font\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,64,86,109,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100508330","phase-3-micronized-progesterone-in-frozen-embryo-transfer-cycles-100508330",false,"NCT05899010","MIcronized PROgesterone in Frozen Embryo Transfer Cycles","A Phase III Randomized Controlled Trial Comparing the Efficacy, Safety and Tolerability of Two Formulations of Vaginal Micronized Progesterone","MI-PROF","Inclusion Criteria:\n\n* Endometrial preparation with hormone replacement therapy\n* Age 18-43 years following an autologous IVF cycle (with or without preimplantation genetic testing for aneuploidy)\n* Age \\\u003C 50 years following an egg donation cycle\n* BMI \\> 18 and \\\u003C 30 kg\u002Fm2\n* blastocyst embryo transfer\n* Willing to participate in the study\n* Able to come to the Center to comply with the procedures of the study: blood tests, appointments and drug dispensation.\n\nExlusion Criteria:\n\n* • Uterine diseases (e.g. submucosal fibroids, polyps, previously diagnosed Müllerian abnormalities)\n* Hydrosalpinx\n* Recurrent pregnancy loss (≥ 3 previous miscarriages)\n* Recurrent implantation failure (≥ 3 previously failed embryo transfers of good-quality blastocysts)\n* Allergy to study medication\n* Pregnancy or lactation\n* Contraindication for hormonal treatment\n* Personalized initiation of exogenous progesterone according to a previous endometrial receptivity assay test\n* Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment).","FEMALE","18 Years","50 Years",{"count":21,"type":22},1020,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This randomized trial was designed as non-inferiority trial aiming to compare ongoing pregnancy rates following LPS with 600 mg\u002Fday vs 800 mg\u002Fday vaginal VMP. All patients will undergo an artificial cycle frozen embryo transfer (AC-FET) with transdermal estradiol 6mg\u002Fday Patients undergoing an artificial cycle FET will start estrogen priming with transdermal estradiol 6mg\u002Fday (Estrogel®) on cycle D1-D3. Following 10-12 days of estrogen priming, patients will be randomized to luteal phase support with a standard formulation (200mg tid, Utrogestan®) or a new formulation (400mg bid) VMP. All patients will undergo a serum P measurement on the day before embryo transfer (ET). Patients with P\\\u003C10 ng\u002Fml will receive a supplement of oral micronized progesterone 300mg, while patients with P≥10ng\u002Fml will maintain the previous luteal phase support (LPS) protocol",[28],"Infertility","RECRUITING","2026-03-25",{"date":32,"type":33},"2026-03-30","ACTUAL",{"date":35,"type":33},"2023-07-05",{"date":37,"type":22},"2028-04",{"name":39,"class":40},"Fundación Santiago Dexeus Font","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100417691","phase-4-personalized-addition-of-recombinant-lh-in-ovarian-stimulation-100417691","NCT04719000","PErsonalized Addition of Recombinant LH in Ovarian Stimulation","PErsonalized Addition of Recombinant LH in Suboptimal Responders >35 Years Old (POSEIDON Group 2): A Randomized Controlled Trial","PEARL","Inclusion Criteria:\n\n* Able and willing to sign the Patient Consent Form and adhere to study visitation schedule.\n* ≥ 35 years ≤40 years old.\n* AFC ≥5 and or AMH ≥1.2 ng\u002FmL.\n* \\\u003C4 or 4-9 oocytes retrieved in a previous IVF\u002FICSI cycle with a starting dose of ≤225 IU with any gonadotropin under a GnRH antagonist protocol.\n* Up to 3 previous ovarian stimulation cycles with a starting dose of ≤225 IU in which dose adjustments during stimulation did not exceed 300 IU.\n* Ovarian stimulation for IVF\u002FICSI\n\nExclusion Criteria:\n\n* Poor ovarian responders according to the Bologna criteria.\n* Polycystic ovary syndrome (PCOS) patients according to the Rotterdam criteria.\n* AFC\\>20.\n* Age \\>40 or \\\u003C35 years old.\n* Women with \\>10 oocytes retrieved in a previous IVF\u002FICSI cycle with 150-225 IU starting dose.\n* Women who required dose adjustments during stimulation \\>300 IU with any gonadotropin in their previous cycle\n* Uterine abnormalities.\n* Recent history of any current untreated endocrine abnormality.\n* Unilateral or bilateral hydrosalpinx (visible on ultrasound scan (USS), unless clipped).\n* Contraindications for the use of medicine used for ovarian stimulation (gonadotropins, GnRH antagonist, progesterone vaginal gel)\n* Recent history of severe disease requiring regular treatment (Clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment and patients with any contraindication to pregnancy).\n* Preimplantation Genetic Testing for Aneuploidies (PGT-a).\n* Testicular Sperm Aspiration or Testicular Sperm Extraction (TESA or TESE)","35 Years","40 Years",{"count":53,"type":22},120,[55],"PHASE4","Different ovarian stimulation regimens have shown to modify late follicular phase hormonal profiles. Besides, recent studies confirm that progesterone levels and their variation in the last day of oocyte maturation are affected by the dose of gonadotropins administered and by other factors. Progesterone elevation in late follicular phase of in vitro fertilization\u002Fintracytoplasmatic sperm injection (IVF\u002FICSI) cycles under ovarian stimulation compromises implantation rates due to a negative effect on the endometrium. However, there is still conflict in the literature questioning whether progesterone levels alone on the triggering day is a sufficient indicator as progesterone does not give the full picture of the ovarian functions, number of follicles as well as estrogen production that facilitate endometrial growth, thus some studies suggest that especially in aged and poor responders Progesterone\u002FEstrogen (P4\u002FE2) ratio has a better reflection (Progesterone (ng\u002FmL) ×1,000\u002Festradiol(pg\u002FmL)) on the ovarian function.\n\nThe scope of the current pilot study is to compare serum progesterone levels as well as P4\u002FE2 ratio on the day of ovulation triggering of women belonging to POSEIDON category group 2 who undergo a new ovarian stimulation with a dose of rhFSH 300 IU or 300 IU rhFSH plus 150 IU recombinant human luteinizing hormone (rhLH) in a gonadotropin-releasing hormone (GnRH) antagonist protocol.",[28],{"date":32,"type":33},{"date":60,"type":33},"2021-02-04",{"date":62,"type":22},"2027-11",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100430093","sex-or-no-sex-that-is-the-question-100430093","NCT04880590","Sex or no Sex: That is the Question.","Sex or no Sex: That is the Question. Impact of Coital Sexual Intercourse on the Clinical Pregnancy Rate After Embryo Transfer.","Inclusion Criteria:\n\n* Women with a heterosexual sexual relationship\n* That they carry out an embryo transfer, in a FET cycle\n\nExclusion Criteria:\n\n* Exclusion criteria are not foreseen",{"count":72,"type":22},2500,"OBSERVATIONAL","This study aims to evaluate the impact of sexual intercourse and orgasm in the 72 hrs following embryo transfer of blastocysts on the clinical pregnancy rate.\n\nAn impact on sexual activity and a decrease in the frequency of intercourse has been observed in infertile couples. In couples who undergo assisted reproductive technology (ART), sexual relations have an additional component that can condition them, such as the fear of influencing the outcome of the cycle.\n\nThe usual practice in ART cycles has evolved towards a preference for blastocyst-stage embryo transfer, both in fresh in vitro fertilization (IVF) cycles and in frozen embryo transfer (FET) cycles.\n\nThe investigators consider it important to elucidate whether coital intercourse after embryo transfer (ET) has an impact on the clinical pregnancy rate after the transfer of blastocyst-stage embryos.",[76,77],"Infertility, Female","Sexual Intercourse","2025-03-10",{"date":80,"type":33},"2025-03-11",{"date":82,"type":33},"2021-05-04",{"date":84,"type":22},"2026-02",{"name":39,"class":40},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100564927","one-shot-ovarian-stimulation-protocol-one-shot-100564927","NCT06635538","One-shot Ovarian Stimulation Protocol (One-shot)","One-Shot Ovarian Stimulation Protocol: A Pilot Study Investigating the Endocrine Profile","One-shot","Inclusion Criteria:\n\nAge \\\u003C= 40\n\nAMH (Anti-Mullerian Hormone) 1.2-3.5 ng\u002Fml or AFC 7-20\n\nNo family history of hereditary or chromosomal diseases\n\nBody mass index (BMI) 18 to 30 kg\u002Fm2",{"count":95,"type":22},20,[97],"NA","The current prospective observational pilot study aims to evaluate the endocrine profile of a single-injection protocol (single CFA + daily oral administration of CC).",[76],"2025-02-25",{"date":102,"type":33},"2025-02-26",{"date":104,"type":33},"2024-10-31",{"date":106,"type":22},"2025-04",{"name":39,"class":40},3,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":41},"100527924","phase-4-intensity-of-ovarian-stimualtion-and-euploid-embryos-100527924","NCT06154083","INtensity of OVarian Stimualtion and Euploid Embryos","The Impact of Ovarian Stimulation Intensity on Embryo Euploidy in Advanced Age Women","INOVEE","Inclusion Criteria:\n\n* Infertile patients with indication for IVF\n* Undergoing preimplantation genetic screening cycles\n* AMH \\>= 1.5 ng\u002Fml and \\\u003C 3.5 ng\u002Fml (AMH result of up to one year will be valid)\n* BMI 18.5 - 30 Kg\u002Fm2\n\nExclusion Criteria:\n\n* Severe male factor requiring TESE (testicular sperm extraction)\n* AMH \\\u003C 1.5 ng\u002Fml or \\>= 3.5 ng\u002Fml\n* Administration of any other drug potentially interfering with the treatment\n* Contraindication for hormonal treatment\n* Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment).\n* Monogenic disease to be detected with PGT-M","38 Years","42 Years",{"count":120,"type":22},110,[55],"This randomized trial was designed as a no-inferiority trial aiming to evaluate if the intensity of stimulation (a milder vs a more intense approach) may have an impact on the number of euploid embryos and the morpho kinetic parameters in advanced age women undergoing PGT-A with a PPOS protocol.",[124],"Fertility",{"date":126,"type":33},"2025-02-27",{"date":128,"type":33},"2023-12-12",{"date":130,"type":22},"2026-05-15",{"name":39,"class":40},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":41},"100548821","phase-4-efficacy-of-the-use-of-cellular-matrix-a-cp-ha-kit-100548821","NCT06425978","Efficacy of the Use of Cellular Matrix\u002F A-CP-HA Kit","The Efficacy of the Use of Cellular Matrix \u002F A-CP-HA Kit (Combination of Autologous Platelet-rich Plasma and Non-cross-linked Hyaluronic Acid) Compared to Local Estrogen Therapy (Blissel, Estriol 50 Micrograms\u002Fg Vaginal Gel) in Women With Genitourinary Syndrome of Menopause. A Randomized Controlled Trial, With a Second Blind Observer.","CellularMatrix","Inclusion Criteria:\n\n* Women ≤70 years old\n* Women that are sexually active\n* Women who report symptoms and signs of SGM, with a vaginal health index (VHIS - Bachmann score) \\\u003C 15 points.\n* Women who understand the Spanish language\n* Willing to participate in the study and sign informed consent.\n\nExclusion Criteria:\n\n* Systemic or local hormonal treatment in the last 3 months\n* Tamoxifen or Aromatase inhibitor treatments\n* Vulvovaginal pathologies (condyloma, vaginal intraepithelial neoplasia, vaginal carcinoma, lichen sclerosus, lichen planus, history of radiation, history of cervical cancer, other gynecologic cancer, or pelvic radiation, or active genital infection (eg. g., bacterial vaginosis, genital herpes, candida) Contraindication for vaginal estrogen therapy\n* Women with thrombocytopenia or coagulation disorders, systemic infections, STDs, cancer of any type in recent treatment, connective tissue diseases.\n* Women who have had pelvic surgery within 6 months.\n* Women who are unwilling or unable to give informed consent and\u002For do not comply with the study requirements.","70 Years",{"count":142,"type":22},192,[55],"This study is a randomized, controlled, non-inferiority trial, that will be performed on 192 women on Menopause (absence of menstruation for at least 12 months), with diagnostic of genitourinary syndrome of menopause (SGM) and a vaginal health index \\\u003C15 points, that are sexually active.\n\nPatients will be randomized 1:1, equal number assigned to each of the two treatment groups, to receive treatment with two dose of Cellular Matrix \u002F A-CP-HA Kit (a combination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid) separated for a month, and control group that will receive the standard treatment for SGM, local estrogen therapy (Blissel, estriol 50 micrograms\u002Fg vaginal gel).\n\nBoth groups will be follow-up for 3 and 6 month afther treatment, a blind observer will assess the application of the validated scale (VHIS, VHI), and the investigators will do the FSD, symptom record, maturation index, follow-up photography and evaluation of adverse events and treatment compliance and adherence.",[146],"Genitourinary Syndrome of Menopause","2024-07-15",{"date":149,"type":33},"2024-07-16",{"date":151,"type":33},"2024-05-30",{"date":153,"type":22},"2026-08",{"name":39,"class":40},""]